TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03172208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 1 iv (single-dose)
Description: Single intravenous (iv) administration of Caplacizumab Dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 iv (single-dose)
Description: Single intravenous (iv) administration of Caplacizumab Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 iv (single-dose)
Description: Single intravenous (iv) administration of Caplacizumab Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 sc (single-dose)
Description: Single subcutaneous (sc) administration of Caplacizumab Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 sc (single-dose)
Description: Single subcutaneous (sc) administration of Caplacizumab Dose 2
Study: NCT02802059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EcN-Suspension
Description: Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).
Study: NCT02772354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Verapamil 20-240 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVI-STAR® RMT ThermoCool
Study: NCT03196505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 266 MG Per 20 ML Injection
Description: Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Study: NCT03172208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 sc (multiple-dose)
Description: Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv (single-dose)
Description: Single intravenous (iv) administration of Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv (single-dose)
Description: Single intravenous (iv) administration of Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv (single-dose)
Description: Single intravenous (iv) administration of Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc (single-dose)
Description: Single subcutaneous (sc) administration of Placebo
Study: NCT03196505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Study: NCT02344069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen
Description: Human fibrinogen concentrate as a injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9% as a injection
Study: NCT01911624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: direct thrombin inhibition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Study: NCT02555644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV
Study: NCT06679439

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical correction of lower eyelid retraction using autologous cartilage
Description: Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous auricular cartilage graft spacer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical correction of lower eyelid retraction using autogenous dermis graft spacer.
Description: Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous dermis graft spacer.
Study: NCT00962494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer: Thriving and Surviving Online Workshop
Study: NCT02890225

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3 days after
Description: in 3 days after RIRS.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 10days after
Description: in10 days after RIRS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EPVL performed in30days after RIRS
Description: Patients in Group C undergo EPVL in630days after RIRS.
Study: NCT01004445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin (BAY41-6551)
Description: Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin (BAY41-6551)
Description: Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two aerosol treatments per day (one treatment every 12hr)
Study: NCT01999088

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Meet
Description: During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Meet
Description: During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Meat
Description: During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Meat
Description: During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
Study: NCT04561713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality task
Description: Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality task
Description: Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
Study: NCT03604432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: propylactic maze
Description: Prophylactic limited left sided maze procedure for subjects in the treatment arm
Study: NCT02846883

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 million MSCs/kg
Description: Intravenous infusion of 1 million allogeneic MSCs/kg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3 million MSCs/kg
Description: Intravenous infusion of 3 million allogeneic MSCs/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of Plasmalyte A (placebo)
Study: NCT00930241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: Advagraf® (one daily dose of Tacrolimus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf®
Description: Prograf® (two daily doses of Tacrolimus)
Study: NCT04068987

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI parametric mapping
Description: Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI parametric mapping
Description: Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body
Study: NCT01780480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dynamic Chinese herbal granule formula
Description: After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
Study: NCT04108832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM OA2
Description: Usage: 3g twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Usage: 3g twice daily
Study: NCT04119557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC
Study: NCT03623841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Participants in control group will do treadmill training only
Study: NCT04046237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year.
Study: NCT02293161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2618960
Description: GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2618960
Description: GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is Sodium Chloride Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is Sodium Chloride Intravenous Infusion
Study: NCT02623140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofreedom
Description: PCI with Biofreedom stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: PCI with Orsiro stent
Study: NCT00003591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02552589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amine fluoride
Description: toothpaste

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: toothpaste
Study: NCT02515396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMI-0100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMI-0100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01361568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: Single i.v. dose (0.04 mg/kg) administered preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single i.v. dose administered preoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: Single i.v. dose (0.04 mg/kg) administered postoperatively for pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single i.v. dose administered postoperatively for pain
Study: NCT04786938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii-Containing Product in Oral Dose Form
Description: S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
Study: NCT06151132

Intervention type: PROCEDURE
Intervention: Direct current cardioversion
Description: Direct current cardioversion to maintain sinus rhythm during rhythm control strategy
Study: NCT03172208

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc (single-dose)
Description: Single subcutaneous (sc) administration of Placebo
Study: NCT01846390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg D1 - D4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
Study: NCT01234831

Intervention type: DEVICE
Group type: OTHER
Intervention: nucleic acid amplification of nasal swab; nasal swab culture
Description: Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal swab culture
Description: Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
Study: NCT02021227

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early chair sitting exercise
Description: A chair sitting exercise will be done at least once a day and for \> 1 hour
Study: NCT02405780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKB327
Description: Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
Study: NCT01773252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Detection System
Study: NCT00302107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-a-like placebo tablets under double-blind conditions
Study: NCT02197273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care analgesia
Study: NCT00499239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9219
Description: GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days.
Study: NCT02437812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin with standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard chemotherapy
Study: NCT01823302

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: nutrition counseling plus oral milk-based nutritional supplement
Description: Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.

Intervention type: OTHER
Group type: OTHER
Intervention: nutritional counseling
Description: nutritional counseling
Study: NCT02168127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: PRC-063
Description: Methylphenidate Hydrochloride Extended-Release Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-063
Description: Methylphenidate Hydrochloride Extended-Release Capsules
Study: NCT00834223

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquashunt
Description: A shunt which is implanted into the suprachoroidal space.
Study: NCT03555760

Intervention type: BEHAVIORAL
Intervention: Observation of informed consent form readings of all patients who are scheduled for surgery
Description: All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
Study: NCT02555644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered IV
Study: NCT03451578

Intervention type: DEVICE
Group type: OTHER
Intervention: Alpha MSH assay
Description: Assay to detect levels of alpha MSH in intraocular fluid.
Study: NCT02195336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dMRT
Description: Baseline, day 8, day 28, day 92, progression/relapse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel and carboplatin
Description: Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
Study: NCT04234074

Intervention type: DEVICE
Group type: OTHER
Intervention: Volusense paediatric monitoring device
Description: Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
Study: NCT03602430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Native vitamin D dose of 200IU to be given once per month to hemodialysis patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
Study: NCT02738034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cogmed
Description: The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cogmed
Description: The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
Study: NCT01910961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limb RIPC
Description: LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
Study: NCT00775073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus, Bevacizumab
Description: Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
Study: NCT00529334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Partial Breast Irradiation
Description: Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.